anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objectives or purpose. The purpose of this project is to measure overall developmental status before, during, and after Otteroo experience. Study population or sample characteristics. Participants will be 4 pre-locomotor infants or young children for whom a healthcare provider or caregiver has identified concerns about potential developmental delay. Study methodology. A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). Study endpoints or outcomes. The end of the study is the final assessment at 12 weeks. Follow-up. None. Statistics and plans for analysis. Researchers will calculate descriptive statistics (mean, range, coefficient of variation) for all measures and describe changes over time, relating the participant's performance at each time point to norm-referenced results for their age.
The anti-lymph cancer medicine is prepared from wild anti-cancer Chinese herbal medicines in Riping county of Guizhou province, shikim, fel bovis seu Bubali, herba Gei Piloselloidis, radix rehmanniae, radix Zanthoxyli Spinifolii, and herba Euphorbiae Humifusae, etc., respectively: oral and topical medicines. The method adopts a multi-way administration mode, and is a novel method for killing cancer cells by using immunotherapy and local confining arithmetic, wherein target blood confining control, key treatment and key breakthrough are carried out around a focus. It overcomes the three medical problems of great side effect, easy recurrence, transfer and diffusion when using operation, chemotherapy and radiotherapy to treat tumor. And can prevent the formation of various gynecological tumors, and has high cure rate and simple and convenient use method for various superficial benign and malignant tumors (cancers). Can be used for combination in surgery, radiotherapy and chemotherapy, or for single treatment. The cure rate of the traditional Chinese medicine composition is 80 percent for lymph cancer and various superficial cancers, and the traditional Chinese medicine composition creates the conditions for curing and prolonging the life of patients who have metastasis, diffusion and difficulty in drinking and taking medicine for patients with advanced cancer. The method is a novel method for killing cancer cells by using immunotherapy and local containment arithmetic, and has the advantages of simultaneous treatment and treatment based on syndrome differentiation, target blood containment, key treatment and key breakthrough around focus of infection. It overcomes the three medical problems of great side effect, easy recurrence, metastasis and diffusion when using operation, chemotherapy and radiotherapy to treat tumors. And can prevent the generation and formation of various tumors, and particularly play a positive role in preventing benign and malignant lymphoma of gynecological tumors. The four-combined anticancer ABC series has no obvious adverse reaction to human body in the treatment dosage. Can be used for combination in surgery, radiotherapy and chemotherapy, and can also be used for consolidation treatment after surgery and radiotherapy to prevent recurrence, diffusion and metastasis. But also can treat various tumors independently. Such as cervical cancer, breast cancer, esophageal cancer, liver cancer, rectal cancer, gastric cancer, various lymph cancers, condyloma acuminatum, uterine tumor, cyst, cervical erosion, etc. The clinical use of the medicine and the use method for years shows that the effective rate of the medicine for the patients with early, middle and late cancers is 100 percent, the cure rate is 80 percent, and the medicine creates cure and or life prolonging conditions for the patients with late cancers and the patients who have metastasis, diffusion and difficulty in taking and drinking the medicine.
PURPOSE:To obtain a hepatic fibrogenetic inhibitor, containing pantethine as an active ingredient, capable of significantly suppressing rise in enzymic activity of proline hydrolase in the liver due to cholesterol load and useful for hepatopathy. CONSTITUTION:A hepatic fibrogenetic inhibitor containing pantethine as an active ingredient. The pantethine is a highly safe compound. The above- mentioned inhibitor can be produced in a dosage form of tablet, powder, granule, capsule or injection. The pharmaceutical is prepared by using the active ingredient and further an excipient, such as starch or cellulose, and an additive, such as disintegrating agent or stabilizer, in combination. The afore-mentioned inhibitor is normally orally and parenterally administered and the dose thereof for an adult in oral administration is within the range of 200-2,000mg/day.
Background and Objectives: Therapeutic hypothermia (TH) shows promise as an approach with neuroprotective effects, capable of reducing secondary brain damage and intracranial pressure following successful mechanical thrombectomy in the acute phase. However, its effect on cognitive impairment remains unclear. This study investigated whether TH can improve cognitive impairment in a mouse model of transient middle cerebral artery occlusion followed by reperfusion (tMCAO/R). Materials and Methods: Nine-week-old C57BL/6N mice (male) were randomly assigned to three groups: sham, tMCAO/R, and tMCAO/R with TH. Cognitive function was assessed 1 month after model induction using the Y-maze test, and regional cerebral glucose metabolism was measured through positron emission tomography with fluorine-18 fluorodeoxyglucose. Results: tMCAO/R induced cognitive impairment, which showed improvement with TH. The TH group exhibited a significant recovery in cerebral glucose metabolism in the thalamus compared to the tMCAO/R group. Conclusions: These findings indicate that TH may hold promise as a therapeutic strategy for alleviating ischemia/reperfusion-induced cognitive impairment.
Designing and predicting novel drug targets to accelerate drug discovery for treating metabolic dysfunction-associated steatohepatitis (MASH)-cirrhosis is a challenging task. The presence of superimposed (nested) and co-occurring clinical and histological phenotypes, namely MASH and cirrhosis, may partly explain this. Thus, in this scenario, each sub-phenotype has its own set of pathophysiological mechanisms, triggers, and processes. Here, we used gene/protein and set enrichment analysis to predict druggable pathways for the treatment of MASH-cirrhosis. Our findings indicate that the pathogenesis of MASH-cirrhosis can be explained by perturbations in multiple, simultaneous, and overlapping molecular processes. In this scenario, each sub-phenotype has its own set of pathophysiological mechanisms, triggers, and processes. Therefore, we used systems biology modeling to provide evidence that MASH and cirrhosis paradoxically present unique and distinct as well as common disease mechanisms, including a network of molecular targets. More importantly, pathway analysis revealed straightforward results consistent with modulation of the immune response, cell cycle control, and epigenetic regulation. In conclusion, the selection of potential therapies for MASH-cirrhosis should be guided by a better understanding of the underlying biological processes and molecular perturbations that progressively damage liver tissue and its underlying structure. Therapeutic options for patients with MASH may not necessarily be of choice for MASH cirrhosis. Therefore, the biology of the disease and the processes associated with its natural history must be at the forefront of the decision-making process.
PURPOSE:To provide the title cosmetic stock to be used in such a manner as to coat the face therewith in taking a bath and be rinsed in finishing a bath, thus adequately percutaneously absorbable for the medicinal ingredient contained, containing a water soluble polymer, a specific hydrophilic surfactant and a water-soluble medicinal ingredient. CONSTITUTION:The objective cosmetic stock containing (A) 0.1-20wt.% of a water-soluble polymer, pref. a partially neutralized salt of polyacrylic acid (esp. alkali metal salt), (B) 0.1-20wt.% of a hydrophilic surfactant selected from B1: polyethylene glycol dialkyl esters (pref. with the molecular weight of the polyethylene glycol fraction of 400-1000 and carbon atom number for the alkyl group of 12-18) and B2: ethylene oxide-bound (by addition reaction)hardened castor oil (pref. with the added mol number of 10-30) and (C) a water-soluble medicinal ingredient. Action of the component B will promote the penetration of the medicinal ingredient into the skin, and the networking action of the component A in the rinsing will retain the medicinal ingredient within and on the skin.
The term "progressive pulmonary fibrosis" or "PPF" is generally used to describe progressive lung fibrosis in an individual with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). Several sets of criteria have been proposed for the identification of PPF, most of which are based on a combination of a decline in forced vital capacity, worsening of respiratory symptoms, and increase in the extent of fibrosis on radiology. Although some risk factors for faster progression of fibrosing ILD have been identified, it remains challenging to predict which individuals will develop PPF. Close monitoring, including regular pulmonary function tests, is required to detect the earliest signs of worsening disease. PPF is associated with high rates of hospitalization and death. Management of PPF requires a multidisciplinary and multimodal approach, including pharmacological therapy and supportive care. Discussions about palliative care should begin at an early stage, individualized to the needs of the patient.
The invention discloses application of 7-methoxy-8-isopentenycoumarin in medicine, and belongs to the field of research and development of new drugs. The immune balance of the body is regulated by an immune system through different cytokines such as TNF-alpha (tumor necrosis factor-alpha), IL-4 (interleukin-4), INF-gamma (interferon-gamma) secreted by various immune cells. If immune cytokines in vivo are in disorder, too high or too low content of immune cytokines can lead to diseases. By establishing a TNF-alpha-luc (tumor necrosis factor-alpha-luciferase) transgene, a mouse drug screening model is reported, and the situation that 7-methoxy-8-isopentenycoumarin can better inhibit the secretion of TNF-alpha are found by screening. TNF-alpha is a proinflammatory cytokine, and the abnormally high expression of the TNF-alpha can lead to autoimmune diseases such as rheumatoid arthritis and psoriasis. Based on a regulatory mechanism of an immune system, the small-molecule drug can inhibit the expression of the TNF-alpha, and thus is expected to be developed into an anti-inflammatory drug used for the treatment of inflammatory diseases.
Heart failure is a common condition that affects approximately 5 million people in the United States, with 550,000 new cases diagnosed each year. Common symptoms of heart failure include swelling and fluid buildup in the legs, feet, and/or lungs; shortness of breath; coughing; elevated heart rate; change in appetite; and fatigue. If left untreated, the condition of the heart may deteriorate so far that the person undergoes ADHF. The number of hospitalizations attributed to ADHF has risen significantly, with many people readmitted soon after discharge because of recurring symptoms or further medical complications, such as cardiorenal syndrome. Current heart failure treatments focus on removing excess fluid buildup, often by increasing urination with diuretic medications or by draining directly from the veins. Direct drainage from the veins, also known as ultrafiltration, may be the more effective method for treating people with ADHF and cardiorenal syndrome. This study will compare the safety and effectiveness of ultrafiltration versus standard medical drug therapy in improving renal function and relieving fluid buildup in people hospitalized with ADHF and cardiorenal syndrome.

Participation in this study will last 60 days. All potential participants will undergo initial screening, which will include a medical history, physical exam, blood draws, measurements of fluid intake and urine output, and questionnaires. These same evaluations and procedures will be repeated at various points during the hospital stay. Eligible participants will be randomly assigned to receive standard medical drug therapy or fluid removal by ultrafiltration. Standard medical drug therapy will involve the intravenous delivery of diuretics and possibly other doctor-recommended medications. Ultrafiltration will involve intravenously removing blood, passing it through an ultrafiltration device, and then returning the blood to the participant. During ultrafiltration, participants will be treated with a blood thinner through the IV, as well.

Follow-up assessments will occur at Days 30 and 60 after treatment. Follow-up assessments will include measurements of fluid intake, urine output, and vital signs; blood draws; physical exams; and questions about medications and status of recovery.
PROBLEM TO BE SOLVED: To obtain an additive for preparations, capable of being utilized as a diluent of effective components in the fields of food, medicament, feed, or the like, having various uses and hardly reacting with the effective components. SOLUTION: This additive for preparations is used in a composition including no effective component having a primary amine and comprises trehalose. The additive is readily soluble in water, becomes a colorless and transparent aqueous solution having low viscosity, has slight sweetness and is excellent in a dose feeling. The powder of the additive is excellent in miscibility, granulating property, compressive moldability and shows a good fluidity. The additive is pharmaceutically stable, hardly reacts with effective components and doesn't cause drug interaction. Since the additive has the above advantages, it is useful as fillers for solid preparations, diluents for liquid preparations, or the like.
BACKGROUND: Chronic constipation (CC) is defined by symptom criteria reflecting heterogenous physiology. However, many patients with CC have significant psychological comorbidities-an alternative definition using a biopsychosocial classification model could be warranted to inform future treatments. We sought to: (1) empirically derive psychological symptom profiles of patients with CC using latent profile analysis and (2) validate these profiles by comparing them on symptom severity, GI-specific anxiety, body mass index (BMI), and anorectal manometry findings.
METHODS: Participants included adults presenting for anorectal manometry for CC (N = 468, 82% female, Mage = 47). Depression/anxiety symptoms and eating disorder (ED) symptoms (EAT-26) were used as indicators (i.e., variables used to derive profiles) representing unique psychological constructs. Constipation symptoms, GI-specific anxiety, BMI, and anorectal manometry results were used as validators (i.e., variables used to examine the clinical utility of the resulting profiles).
KEY RESULTS: A 5-profile solution provided the best statistical fit, comprising the following latent profiles (LPs): LP1 termed "high dieting, low bulimia;" LP2 termed "high ED symptoms;" LP3 termed "moderate ED symptoms;" LP4 termed "high anxiety and depression, low ED symptoms;" and LP5 termed "low psychological symptoms." The low psychological symptom profile (61% of the sample) had lower abdominal and overall constipation severity and lower GI-specific anxiety compared to the four profiles characterized by higher psychological symptoms (of any type). Profiles did not significantly differ on BMI or anorectal manometry results.
CONCLUSIONS AND INFERENCES: Profiles with high psychological symptoms had increased constipation symptom severity and GI-specific anxiety in adults with CC. Future research should test whether these profiles predict differential treatment outcomes.
OBJECTIVE: To find out whether the use of indocyanine green for lymphatic sparing in the laparoscopic Palomo technique reduces the incidence of postoperative hydrocele.
MATERIALS AND METHODS: A comparative cohort study of varicocele patients treated with the laparoscopic Palomo technique from 2008 to 2023 was carried out. Patients were divided into two groups according to whether fluorescence lymphography (intratesticular indocyanine green) had been performed or not. Epidemiological, surgical, and clinical data, as well as complications, were recorded. A hypothesis test was conducted using the SPSS software.
RESULTS: 30 patients undergoing varicocele surgery through the laparoscopic Palomo technique were included. They were divided into two groups -lymphatic sparing (n= 13) vs. spermatic vessel ligation without sparing (n= 17). Mean age at surgery was 14 years. 5 cases of postoperative hydrocele were identified in the no lymphatic sparing group. 1 of them required surgery for hydrocele treatment. No hydrocele cases were noted in the lymphography group. The difference was statistically significant (p= 0.032). There were no statistically significant differences in terms of operating times or mean hospital stay. No recurrences, postoperative testicular atrophies, or indocyanine-green-related complications were recorded. Mean follow-up was 11.4 months.
CONCLUSIONS: The use of indocyanine green for lymphatic sparing in the treatment of varicocele through the laparoscopic Palomo technique significantly reduces the incidence of postoperative hydrocele.
Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
The present invention relates to a cyclophosphamide liposome and its preparation method. It is a liposome or precursor liposome prepared by using cyclophosphamide and auxiliary materials of phospholipid and cholesterol, in which the auxiliary materials of supporting agent, etc. also can be added. The film material phospholipid can adopt natural phospholipid or synthetic phospholipid, the weight ratio of phospholipid and medicine is 0.1:1-50:1, Its preparation method can adopt ethyl alcohol injection method, film dispersion method, inverted evaporation method, extrusion method and mechanical method. The supporting agent can be sorbitol, mannitol, cane sugar, sodium chloride, water soluble starch, dextran, glucose and lactose, the ratio of supporting agent and phospholipid is 0.01:1-500:1. Said invention can produce action of resisting tumor.
PURPOSE:To obtain a skin cosmetic providing preventing effects on stain and freckles even after washing away, providing effects of fair skin, containing hinokithiol. CONSTITUTION:A skin cleaner containing hinokithiol. Hinokithiol extracted from a hinoki oil from Taiwan or a hinoki oil from AOMORI Prefecture or prepared by synthetic method is used as the hinokithiol. The skin cleaner is the general term of toilet soap for washing face and the whole body, medicated soap, deodorant soap, body shampoo, cleansing foam, etc. In the skin cleaner, components thereof are not designated and components used for washing face and the whole body are sufficiently applied. The amount of hinokithiol blended is usually 0.002-15wt.%, preferably 0.15-5.0wt.% based on the whole amount of the skin cleaner.
The present disclosure is directed to a novel apparatus and novel methods for the separation, characterization, and manipulation of matter. The invention combines the use of frequency-dependent dielectric and conductive properties of particulate matter and solubilized matter with the properties of the suspending and transporting medium to discriminate and separate such matter. The apparatus includes a chamber having at least one electrode element and at least one inlet and one output port into which matter are introduced and removed from the chamber. Matter carried through the chamber in a fluid stream is then displaced within the fluid by a dielectrophoretic (DEP) force caused by the energized electrode. Following displacement within the fluid, matter travels through the chamber at velocities according to the velocity profile of the chamber. After the matter has transitted through the chamber, it exits at the opposite end of the chamber at a characteristic position.
Subjects will receive 3 doses NEO-201 in combination with one dose of pembrolizumab in a 42 day cycle. This course will be repeated in the absence of disease progression or unacceptable toxicity.
Strong CYP3A4 Inhibitors

Coadministration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5)].

Strong CYP3A4 Inducers

Coadministration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5)].
Esophageal cancer is one of the most common malignant tumor in China. In Asian countries, esophageal squamous cell carcinoma is the main pathological type of esophageal carcinoma. Prognosis of esophageal squamous cell carcinoma is usually poor and surgery is the only radical treatment. Cisplatin (DDP, cisplatin), 5 - Fluorouracil (5 - Fluorouracil, 5 - FU) and taxane are the most adopted chemotherapy agents, with efficacy rates of 33%-40% as first-line treatment for metastatic or recurrent esophageal squamous carcinoma and a median overall survival of 6-10 months. New agents were needed. Apatinib Mesylate is a small molecule VEGFR tyrosine kinase inhibitor. The anti-tumor mechanism of Apatinib is inhibiting angiogenesis in malignancy by inhibiting VEGFR. Apatinib Mesylate was approved by CFDA (China Food and Drug Administration) for the treatment of advanced gastric cancer. In the previous clinical practice, we observed that part of the patients with esophageal squamous cell carcinoma were resistant to conventional treatments benefited from Apatinib Mesylate. Based on the research situation mentioned above, we decided to conduct a phase II clinical trial to further explore the efficacy and safety of Apatinib Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments. An exploratory molecular marker analysis will be performed in order to find out the beneficial population of Apatinib Mesylate.
Participants (n=4), will be enrolled in Group 1 (HepB mAb19 3 mg/kg or placebo, single dose) and randomized 3:1 to HepB mAb19 or placebo with each participant being dosed at least 72 hours apart. Following enrollment and administration of study drug in the first two participants, the Protocol Safety Review Team (PSRT) will review available safety data (including safety labs) and only following this review and in the absence of dose limiting toxicities (DLT), the remaining two participants in Group 1 will be enrolled and randomized to HepB mAb19 or placebo.